Grant of Share Options

Cathay International Holdings Limited

("Cathay" or the "Company")

Grant of Share Options

Hong Kong, 2 April 2015 - Cathay International Holdings Ltd. (LSE: CTI.L), an investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China, today announces that on 31 March 2015, the Company granted 4,080,000 options under a share option plan (the "Share Option Plan") approved by shareholders of the Company on 3 June 2010. The 4,080,000 options granted to certain members of the Group's management and employees represent approximately 21.94% of the options currently available under the Share Option Plan. Of the 4,080,000 options granted, the share options granted to directors and senior executives of the Group are as follows:

The exercise price of the options is 20.00 pence per share which is higher than the average closing mid-market price of the Company's common shares of 19.29 pence per share for the 30 trading days immediately prior to the date of grant. The options have a three years vesting period and are exercisable on or before the fifth anniversary of the date of the grant, subject to certain exercise conditions aligned to the Group's results and performance.

For further enquiries, please contact:

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading operator and investor in the growing healthcare sector in the People's Republic of China ("PRC"). Taking advantage of the strong and growing domestic demand for high quality healthcare products in China, Cathay aims to identify investment opportunities with emphasis on high growth healthcare markets and build them into market sector leaders, with a clear exit strategy. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, China's leading specialty pharmaceutical company focused on rheumatology and dermatology; Haizi, a company engaged in the manufacture, marketing and sales of inositol and its by-product, di-calcium phosphate; Yangling, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a private equity investment arm focused on minority investment opportunities and a hotel investment.

For more information please visit the Company's website: www.cathay-intl.com.hk